Business
SciBase's Nevisense (EIS) Included in the US NCCN Guidelines for Melanoma which supports the use of EIS in the detection of melanoma
SciBase Holding AB ("SciBase") (STO: SCIB), a leading developer of AI-based diagnostic solutions for skin disorders, today announced that Nevisense (EIS) is included in the US National Comprehensive Cancer Network(NCCN) Clinical Practice Guidelines in Oncology formelanoma. The guidelines refer to EIS as a diagnostic support technology to aid in the detection of melanoma.
About this update from Scibase Holding Ab
[{"type":"text","content":"STOCKHOLM, Feb. 19, 2026 /PRNewswire/ -- SciBase Holding AB ("SciBase") (STO: SCIB), a leading developer of AI-based diagnostic solutions for skin disorders, today announced that Nevisense (EIS) is included in the US National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology for melanoma. The guidelines refer to EIS as a diagnostic support technology to aid in the detection of melanoma. ","length":436,"tagName":"p"},{"type":"text","content":"NCCN develops the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®), which are recognized as the standard for clinical policy and patient care in oncology.","length":170,"tagName":"p"},{"type":"text","content":""The inclusion of Nevisense (electrical impedance spectroscopy) in the NCCN Guidelines underscores the importance of objective technologies in melanoma detection," said Dr. Alexander Meves, MD, dermatologist, professor at the Mayo Clinic College of Medicine. Dr. Alexander Meves added, "Guideline inclusion helps clinicians understand how technologies like Nevisense fit into established clinical strategies focused on earlier detection."","length":458,"tagName":"p"},{"type":"text","content":""Including electrical impedance spectroscopy in these guidelines reflects the ongoing need in melanoma detection to incorporate objective data that improves clinical judgment," said Dr. Darrell Rigel, MD, Clinical Professor of Dermatology at the New York University (NYU), and Past President of the American Academy of Dermatology. "While visual assessment and dermoscopy have long been shown to improve melanoma detection rates, our published clinical research demonstrates that adding Nevisense (EIS) provides a further statistically significant and clinically meaningful improvement."","length":607,"tagName":"p"},{"type":"text","content":""As melanoma incidence continues to rise, the need for earlier and more accurate assessment has never been greater," said Pia Renaudin CEO of SciBase. "NCCN Guidelines highlights the critical role of advanced, non-invasive, point-of-care technologies like Nevisense in helping clinicians detect melanoma earlier and improve outcomes for patients."","length":367,"tagName":"p"},{"type":"text","content":"For further information please contact:","length":3...